Featured Online Programs This is critical because there will always be a percentage of the population that cannot be vaccinated, including infants, young children, the elderly, people with severe allergies, pregnant women, or people with compromised immune systems. Types of Vaccines The key to vaccines is injecting the antigens into the body without causing the person to get sick at the same time. Advantages: Because these vaccines introduce actual live pathogens into the body, it is an excellent simulation for the immune system.
So live attenuated vaccines can result in lifelong immunity with just one or two doses. Disadvantages: Because they contain living pathogens, live attenuated vaccines are not given to people with weakened immune systems, such as people undergoing chemotherapy or HIV treatment, as there is a risk the pathogen could get stronger and cause sickness.
Additionally, these vaccines must be refrigerated at all times so the weakened pathogen doesn't die. Specific Vaccines: Measles Mumps Rubella MMR combined vaccine Varicella chickenpox Influenza nasal spray Rotavirus Inactivated Vaccines: For these vaccines, the specific virus or bacteria is killed with heat or chemicals, and its dead cells are introduced into the body.
Advantages: These vaccines can be freeze dried and easily stored because there is no risk of killing the pathogen as there is with live attenuated vaccines. They are also safer, without the risk of the virus or bacteria mutating back into its disease-causing form. Disadvantages: Because the virus or bacteria is dead, it's not as accurate a simulation of the real thing as a live attenuated virus.
Therefore, it often takes several doses and "booster shots" to train the body to defend itself. Advantages: With these vaccines, the chance of an adverse reaction in the patient is much lower, because only a part or the original pathogen is injected into the body instead of the whole thing.
Disadvantages: Identifying the best antigens in the pathogen for training the immune system and then separating them is not always possible. Only certain vaccines can be produced in this way. Does this mean a vaccine will also fail to protect against the virus? Certainly not. First, it is still unclear how common these reinfections are. More importantly, a fading immune response to natural infection, as seen in the Nevada patient, does not mean we cannot develop a successful, protective vaccine.
Any infection initially activates a non-specific innate immune response, in which white blood cells trigger inflammation. This may be enough to clear the virus. But in more prolonged infections, the adaptive immune system is activated. Here, T and B cells recognise distinct structures or antigens derived from the virus. T cells can detect and kill infected cells, while B cells produce antibodies that neutralise the virus. During a primary infection — that is, the first time a person is infected with a particular virus — this adaptive immune response is delayed.
This protection provided by the mother, however, is short-lived. During the first few months of life, maternal antibody levels in the infant fall, and protection fades by about six months of age. Artificial Passive immunity can be induced artificially when antibodies are given as a medication to a nonimmune individual. These antibodies may come from the pooled and purified blood products of immune people or from non-human immune animals, such as horses. In fact, the earliest antibody-containing preparations used against infectious diseases came from horses, sheep, and rabbits.
Antibodies were first used to treat disease in the late 19 th century as the field of bacteriology was emerging. The first success story involved diphtheria, a dangerous disease that obstructs the throat and airway of those who contract it. In , Shibasaburo Kitasato and Emil von Behring immunized guinea pigs against diphtheria with heat-treated blood products from animals that had recovered from the disease.
The preparations contained antibodies to the diphtheria toxin that protected the guinea pigs if they were exposed soon thereafter to lethal doses of diphtheria bacteria and its toxin.
Next, the scientists showed that they could cure diphtheria in an animal by injecting it with the blood products of an immunized animal. They soon moved to testing the approach on humans and were able to show that blood products from immunized animals could treat diphtheria in humans.
The antibody-containing blood-derived substance was called diphtheria antitoxin, and public boards of health and commercial enterprises began producing and distributing it from onward. Kitasato, von Behring, and other scientists then devoted their attention to treatment of tetanus, smallpox, and bubonic plague with antibody-containing blood products. The use of antibodies to treat specific diseases led to attempts to develop immunizations against the diseases.
Their pioneering work, along with advances in the separation of the antibody-containing blood component, led to many studies on the effectiveness of antibody preparations for immunization against measles and infectious hepatitis. Before the polio vaccine was licensed, health officials had hopes for the use of gamma globulin an antibody-containing blood product to prevent the disease.
William M. He showed that administration of gamma globulin containing known poliovirus antibodies could prevent cases of paralytic polio. However, the limited availability of gamma globulin, and the short-term protection it offered, meant that the treatment could not be used on a wide scale.
The licensure of the inactivated Salk polio vaccine in made reliance on gamma globulin for poliovirus immunization unnecessary. Today, patients may be treated with antibodies when they are ill with diphtheria or cytomegalovirus.
Or, antibody treatment may be used as a preventive measure after exposure to a pathogen to try to stop illness from developing such as with respiratory syncytial virus [RSV], measles, tetanus, hepatitis A, hepatitis B, rabies, or chickenpox.
Antibody treatment may not be used for routine cases of these diseases, but it may be beneficial to high-risk individuals, such as people with immune system deficiencies.
Vaccines typically need time weeks or months to produce protective immunity in an individual and may require several doses over a certain period of time to achieve optimum protection.
Passive immunization, however, has an advantage in that it is quick acting, producing an immune response within hours or days, faster than a vaccine. Additionally, passive immunization can override a deficient immune system, which is especially helpful in someone who does not respond to immunization. Antibodies, however, have certain disadvantages.
First, antibodies can be difficult and costly to produce. Although new techniques can help produce antibodies in the laboratory, in most cases antibodies to infectious diseases must be harvested from the blood of hundreds or thousands of human donors. Or, they must be obtained from the blood of immune animals as with antibodies that neutralize snake venoms. In the case of antibodies harvested from animals, serious allergic reactions can develop in the recipient.
Another disadvantage is that many antibody treatments must be given via intravenous injection, which is a more time-consuming and potentially complicated procedure than the injection of a vaccine. Finally, the immunity conferred by passive immunization is short lived: it does not lead to the formation of long-lasting memory immune cells.
In certain cases, passive and active immunity may be used together. For example, a person bitten by a rabid animal might receive rabies antibodies passive immunization to create an immediate response and rabies vaccine active immunity to elicit a long-lasting response to this slowly reproducing virus. These antibodies have wide-ranging potential applications to infectious disease and other types of diseases.
Monoclonal antibodies were first created by researchers Cesar Milstein, PhD , and Georges Kohler, PhD , who combined short-lived antibody-producing mouse spleen cells which had been exposed to a certain antigen with long-lived mouse tumor cells.
The combined cells produced antibodies to the targeted antigen. To date, only one MAb treatment is commercially available for the prevention of an infectious disease.
Scientists are researching other new technologies for producing antibodies in the laboratory, such as recombinant systems using yeast cells or viruses and systems combining human cells and mouse cells, or human DNA and mouse DNA. Bioterror threats In the event of the deliberate release of an infectious biological agent, biosecurity experts have suggested that passive immunization could play a role in emergency response.
The appearance of hyperlinks does not constitute endorsement by the Defense Health Agency of non-U. Government sites or the information, products, or services contained therein.
Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations.
Such links are provided consistent with the stated purpose of this website. Need larger text? Immunology Basics What is Immunity? Innate Immunity Innate immunity is the immune system that is present when you are born.
Adaptive Immunity Adaptive immunity is protection that your body builds when it meets and remembers antigens, which is another name for germs and other foreign substances in the body. There are two types of adaptive immunity: active and passive. Active Immunity - antibodies that develop in a person's own immune system after the body is exposed to an antigen through a disease or when you get an immunization i. This type of immunity lasts for a long time.
0コメント